1 ZhangT, YuS, GuoP, et al. Nonmotor symptoms in patients with Parkinson disease: a cross-sectional observational study [J]. Medicine, 2016, 95(50): e5400. 2 黄星会,霍丽涛,吴庆文,等. 帕金森病的非运动症状及研究进展[J]. 中国康复理论与实践, 2013, 19(11): 1013-1015. 3 王刚,崔海伦,刘军,等. 帕金森病发病机制及诊断与治疗转化研究进展[J]. 中国现代神经疾病杂志, 2018, 18(1): 19-24. 4 RizekP, KumarN, JogMS. An update on the diagnosis and treatment of Parkinson disease [J]. CMAJ, 2016, 188(16): 1157-1165. 5 HuangX, AbbottR D, PetrovitchH, et al. Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia Aging Study [J]. Mov Disord, 2010, 23(7): 1013-1018. 6 SimonK C, ChenH, SchwarzschildM, et al. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease [J]. Neurology, 2007, 69(17): 1688-1695. 7 de LauL M, KoudstaalP J, HofmanA, et al. Serum cholesterol levels and the risk of Parkinson's disease [J]. Am J Epidemiol, 2006, 164(10): 998-1002. 8 GuoX, SongW, ChenK, et al. The serum lipid profile of Parkinson's disease patients: a study from China [J]. Int J Neurosci, 2015, 125(11): 838-844. 9 EmamzadehF N, SurguchovA. Parkinson's disease: biomarkers, treatment, and risk factors [J]. Front Neurosci, 2018, 12: 612. 10 PaulR, ChoudhuryA, KumarS, et al. Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: involvement of mitochondrial dysfunctions and oxidative stress [J]. PLoS One, 2017, 12(2): e0171285. 11 中华医学会神经病学分会帕金森病及运动障碍学组. 中国帕金森病的诊断标准(2016版)[J]. 中华神经科杂志, 2016, 49(4): 268-271. 12 SchragA, JahanshahiM, QuinnN. What contributes to quality of life in patients with Parkinson's disease? [J]. J Neurol Neurosurg Psychiatry, 2000, 69(3): 308-312. 13 HoehnM M, YahrM D. Parkinsonism: onset, progression and mortality [J]. Neurology, 2001, 57(3): 11-26. 14 VanceJ E. Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases [J]. Dis Model Mech, 2012, 5(6): 746-755. 15 LiL, LiuM S, LiG Q, et al. Relationship between apolipoprotein superfamily and Parkinson's disease [J]. Chin Med J (Engl), 2017, 130(21): 2616-2623. 16 QiangJ K, WongY C, SiderowfA, et al. Plasma apolipoprotein A1 as a biomarker for Parkinson disease [J]. Ann Neurol, 2013, 74(1): 119-127. 17 WangE S, SunY, GuoJ G, et al. Tetranectin and apolipoprotein A-I in cerebrospinal fluid as potential biomarkers for Parkinson's disease [J]. Acta Neurol Scand, 2010, 122(5): 350-359. 18 GaoX, SimonK C, SchwarzschildM A, et al. Prospective study of statin use and risk of Parkinson disease [J]. Arch Neurol, 2012, 69(3): 380-384. 19 LeeY C, LinC H, WuR M, et al. Discontinuation of statin therapy associates with Parkinson disease: a population-based study [J]. Neurology, 2013, 81(5): 410-416. 20 SwansonC R, LiK, UngerT L, et al. Lower plasma apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotype [J]. Mov Disord, 2015, 30(6): 805-812. 21 LewisT L, CaoD, LuH, et al. Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease [J]. J Biol Chem, 2010, 285(47): 36958-36968. 22 ArenasF, Garcia-RuizC, Fernandez-ChecaJ C. Intracellular cholesterol trafficking and impact in neurodegeneration [J]. Front Mol Neurosci, 2017, 10: 382. 23 LimL, Jackson-LewisV, WongL C, et al. Lanosterol induces mitochondrial uncoupling and protects dopaminergic neurons from cell death in a model for Parkinson's disease [J]. Cell Death Differ, 2012, 19(3): 416-427. 24 HuangX, AuingerP, EberlyS, et al. Serum cholesterol and the progression of Parkinson's disease: results from DATATOP [J]. PLoS One, 2011, 6(8): e22854. 25 BennM, NordestgaardB G, Frikke-SchmidtR, et al. Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study [J]. BMJ, 2017, 357: j1648. 26 LuoL, YuanX, HuangW, et al. Safety of coadministration of ezetimibe and statins in patients with hypercholesterolaemia: a meta-analysis [J]. Intern Med J, 2015, 45(5): 546-557. 27 ZhangL, WangX, WangM, et al. Circulating cholesterol levels may link to the factors influencing Parkinson's risk [J]. Front Neurol, 2017, 8: 501. 28 van der MarkM, NijssenP C, VlaanderenJ, et al. A case-control study of the protective effect of alcohol, coffee, and cigarette consumption on Parkinson disease risk: time-since-cessation modifies the effect of tobacco smoking [J]. PLoS One, 2014, 9(4): e95297. 29 ChenH, HuangX, GuoX, et al. Smoking duration, intensity, and risk of Parkinson disease [J]. Neurology, 2010, 74(11): 878-884. 30 RitzB, LeeP C, LassenC F, et al. Parkinson disease and smoking revisited: ease of quitting is an early sign of the disease [J]. Neurology, 2014, 83(16): 1396-1402. |